PMID: 8592621Jan 1, 1995Paper

Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
C J Danpure

Abstract

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inborn error of glyoxylate metabolism caused by a deficiency of the liver-specific peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT). At the enzymic level, PH1 is usually heterogeneous. Several novel enzymic phenotypes have been identified, including the mistargeting of AGT from the peroxisomes to mitochondria, and the aggregation of AGT in the peroxisomal matrix. Seven PH1-specific point mutations, as well as a number of clinically useful normal polymorphisms, have been found so far in the AGT gene. The molecular elucidation of PH1 has led to changes in almost all aspects of its clinical management, most notably treatment. Liver transplantation as a form of enzyme replacement therapy has been used successfully in the treatment of PH1 over the last 10 years, but the long-term solution lies in gene therapy. Although PH1 is, in many respects, an ideal candidate for gene therapy, the strategies eventually adopted will need to take into account its unique metabolic and enzymic characteristics.

Citations

Jun 13, 2006·Current Gastroenterology Reports·William R Treem
Jan 22, 1998·Clinica Chimica Acta; International Journal of Clinical Chemistry·J M Leiper, C J Danpure
Apr 15, 1999·Clinical Transplantation·A M de MattosD J Norman
Dec 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Eduardo SalidoArmando Torres
Nov 3, 2009·Aging & Mental Health·Christine V Ferri, Rachel A Pruchno
Jun 16, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Christopher J Danpure
Oct 23, 2004·Nephron. Experimental Nephrology·Christopher J Danpure
Jun 18, 2005·American Journal of Nephrology·Neville V Jamieson, UNKNOWN European PHI Transplantation Study Group
Jun 18, 2005·American Journal of Nephrology·John C LieskeDawn S Milliner
Jun 18, 2005·American Journal of Nephrology·Christopher J Danpure
Mar 16, 2012·Journal of Cranio-maxillo-facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery·K T MitsimponasK A Schlegel
Mar 11, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Stephen M S TingR Mark Temple
May 24, 2008·Néphrologie & thérapeutique·Paul JungersMichel Daudon
Apr 25, 2000·The Urologic Clinics of North America·C J Danpure
Feb 27, 2013·Expert Opinion on Pharmacotherapy·Hongshi XuElaine M Worcester
Sep 9, 2009·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Basak DoganavsargilGulcin Basdemir
Aug 30, 2018·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Shimrit Tzvi-BehrChoni Rinat
Oct 19, 2012·The Journal of Veterinary Medical Science·Kavindra Kumara WijesunderaJyoji Yamate
Nov 28, 2000·Annual Review of Genetics·K A Sacksteder, S J Gould
Jun 1, 1997·Journal of Medical Genetics·C von Schnakenburg, G Rumsby
Sep 9, 2016·American Journal of Physiology. Renal Physiology·Ben OliveiraStephen B Walsh
Feb 13, 2021·QJM : Monthly Journal of the Association of Physicians·P ChiddarwarV Indiran
Sep 20, 2001·Journal of the American Society of Nephrology : JASN·Antonio AmorosoMartino Marangella

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Frontiers in Bioscience (Landmark Edition)
Barbara CelliniRiccardo Montioli
© 2021 Meta ULC. All rights reserved